URGN
UroGen Pharma Ltd
NASDAQ: URGN · HEALTHCARE · BIOTECHNOLOGY
$23.83
+2.10% today
Updated 2026-04-30
Market cap
$1.14B
P/E ratio
—
P/S ratio
10.35x
EPS (TTM)
$-3.19
Dividend yield
—
52W range
$3 – $30
Volume
0.8M
UroGen Pharma Ltd (URGN) Earnings
Quarterly earnings history, analyst estimates, and stock price reaction.
EPS beat streak
1 of 8
Last 8 quarters
Avg EPS surprise
-13.4%
Last 4 quarters
Revenue YoY growth
+54.0%
Most recent quarter
EPS YoY growth
+33.8%
Most recent quarter
Earnings surprise history (last 12 quarters)
Beat estimate Missed estimate
Quarterly EPS and revenue trend
Quarterly revenue EPS (diluted)
How the stock reacts to earnings
Avg 1-day reaction
-1.4%
Last 3 reports
Positive reaction rate
33%
1 of 3 quarters
Largest single-day move
+20.4%
2025-11-06
| Report date | EPS actual | Surprise | Close before | Close after | 1-day reaction |
|---|---|---|---|---|---|
| 2026-03-02 | $-0.53 | -9.9% | $21.70 | $18.82 | -13.3% |
| 2025-11-06 | $-0.69 | -1.5% | $19.31 | $23.24 | +20.4% |
| 2025-08-07 | $-1.05 | -26.5% | $20.01 | $17.75 | -11.3% |
Quarterly earnings history
| Fiscal quarter ending | EPS estimate | EPS actual | Surprise | Revenue | YoY revenue |
|---|---|---|---|---|---|
| 2025-12-31 | $-0.48 | $-0.53 | -9.9% | $37.84M | +54.0% |
| 2025-09-30 | $-0.68 | $-0.69 | -1.5% | $27.48M | +9.0% |
| 2025-06-30 | $-0.83 | $-1.05 | -26.5% | $24.21M | +10.8% |
| 2025-03-31 | $-0.80 | $-0.92 | -15.7% | $20.25M | +7.8% |
| 2024-12-31 | $-0.72 | $-0.80 | -11.1% | $24.57M | +4.4% |
| 2024-09-30 | $-0.82 | $-0.55 | +32.9% | $25.20M | +20.9% |
| 2024-06-30 | $-0.83 | $-0.91 | -9.6% | $21.85M | +3.4% |
| 2024-03-31 | $-0.87 | $-0.97 | -11.5% | $18.78M | — |
| 2023-12-31 | $-0.68 | $-0.72 | -5.9% | $23.53M | — |
| 2023-09-30 | $-0.85 | $-0.68 | +20.0% | $20.85M | — |
| 2023-06-30 | $-1.14 | $-1.03 | +9.6% | $21.14M | — |
Frequently asked questions
Has UroGen Pharma Ltd beaten earnings estimates?
UroGen Pharma Ltd has beaten Wall Street EPS estimates in 1 of its last 8 quarterly reports, with an average EPS surprise of -13.4% over the last 4 quarters.
How does URGN stock react to earnings?
URGN stock has moved an average of -1.4% in the trading day following earnings over its last 3 reports, with positive reactions in 33% of those quarters.
What is UroGen Pharma Ltd's revenue growth rate?
UroGen Pharma Ltd reported year-over-year revenue growth of +54.0% in its most recent quarter, with EPS growing +33.8% year-over-year.